Drug intelligence / Profile preview

autologous hyperacute serum

Development stage: Unknown
Lead developer: Orthosera
Administration: Intraarticular

Overview

Autologous hyperacute serum is a biologic regenerative medicine product developed by OrthoSera. It is a patent-protected derivative of platelet-rich plasma (PRP), specifically the serum fraction extracted from platelet-rich fibrin (PRF) during the hyperacute phase of clot formation. Produced at the bedside using the hypACT inject device, the serum is rich in cytokines, growth factors, and structural proteins. It is administered via intra-articular injection to treat knee osteoarthritis and sports injuries. The serum works by modulating the pro-inflammatory cytokine environment within the joint and promoting chondrocyte viability and cartilage regeneration.

Other names: hyperacute serumhypACT

Beyond the preview

Go deeper on autologous hyperacute serum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous hyperacute serum.

Explore the full profile